John W. Mellors
University of Pittsburgh
443 Papers
5.5K Citations
John W. Mellors is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 78, co-authored 373 publications. Previous affiliations of John W. Mellors include East China University of Science and Technology & Case Western Reserve University.
Chat about Author
Papers
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A. Marzinke,Jessica M. Fogel,Estelle Piwowar-Manning,Ryan Kofron,Pradip Bhandari,R. Gollings,Lane R. Bushman,Lei Weng,Elias K. Halvas,John W. Mellors,Peter J. Anderson,Deborah Persaud,Craig W. Hendrix,Marybeth McCauley,Alex R. Rinehart,M H St Clair,S L Ford,James F. Rooney,Adeola Adeyeye,Suwat Chariyalertsak,Kenneth H. Mayer,Roberto C. Arduino,Myron S. Cohen,Beatriz Grinsztejn,Brett Hanscom,Raphael J. Landovitz,Susan H. Eshleman +26 more
TL;DR: HPTN 083 showed that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men as mentioned in this paper .
13
Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173.
Rajesh T. Gandhi,Ronald J. Bosch,Evgenia Aga,Margaret A. Bedison,Barbara Bastow,John L. Schmitz,Janet D. Siliciano,Robert F. Siliciano,Joseph J. Eron,John W. Mellors +9 more
TL;DR: In patients with HIV-1 RNA levels < 200 copies/ml 24-96 weeks after initiating ART, the level of viraemia is positively associated with infectious virus recovery from resting memory CD4 cells, and whether this association persists after longer-term suppressive ART needs to be determined.
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Sarah Palmer,Sarah Palmer,Valerie F. Boltz,Jeremy Y. Chow,Neil A. Martinson,Neil A. Martinson,James McIntyre,Glenda Gray,Mark J. Hopley,Douglas L. Mayers,Patrick A. Robinson,David B. Hall,Frank Maldarelli,John M. Coffin,John W. Mellors +14 more
TL;DR: NVP-resistant variants were detected in about one-third of women despite CBV treatment, but the duration of persistence and clinical impact of these variants in response to antiretroviral therapy is uncertain.
12
Nucleic Acid, Antibody, and Virus Culture Methods to Detect Xenotropic MLV-Related Virus in Human Blood Samples
Mary F. Kearney,KyeongEun Lee,Rachel Bagni,Ann Wiegand,Jonathan Spindler,Frank Maldarelli,Peter A. Pinto,W. M. Linehan,Cathy D. Vocke,Krista A. Delviks-Frankenberry,R. W. deVere White,G. Q. Del Prete,John W. Mellors,Jeffrey D. Lifson,Vineet N. KewalRamani,Vinay K. Pathak,John M. Coffin,S. F. J. Le Grice +17 more
TL;DR: It is demonstrated that while XMRV-related assays developed at the NCI-Frederick can readily measure X MRV nucleic acids, antibodies, and replication competent virus, no evidence ofXMRV was found in the blood of patients with prostate cancer.
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.
Jesse Fajnzylber,Radwa Sharaf,John N. Hutchinson,Evgenia Aga,Ronald J. Bosch,Wendy Hartogensis,Jeffrey M. Jacobson,Elizabeth Connick,Paul A. Volberding,Daniel J Skiest,David J. Margolis,Michael C. Sneller,Susan J. Little,Roy M. Gulick,John W. Mellors,Rajesh T. Gandhi,Robert T. Schooley,Keith Henry,Pablo Tebas,Steve Deeks,Tae-Wook Chun,Ann C. Collier,Frederick Hecht,Jonathan Z. Li,Champ study team +24 more
TL;DR: In this article, an interactive tool for predicting viral rebound timing in analytical treatment interruption (ATI) trials and the impact of post-treatment controller (PTC) definitions on PTC frequency estimates is described.
12